Clinical characteristics of patients with PMS2 mutations.

Authors

null

Samiksha Pandey

William Beaumont Hospital, Royal Oak, MI

Samiksha Pandey , Tara Rangarajan , Dana Zakalik

Organizations

William Beaumont Hospital, Royal Oak, MI, Beaumont Health, Royal Oak, MI

Research Funding

No funding received

Background: Lynch syndrome is a hereditary cancer predisposition syndrome caused by mutations in mismatch repair genes, MLH1, MSH2, MSH6, and PMS2. The cancer risks and clinical presentation of PMS2 associated Lynch syndrome is not well defined. This study outlines the characteristics of patients with PMS2 mutations identified in a large academic center. Methods: Patients with a pathogenic or likely pathogenic PMS2 variant identified between June 1, 2009 and Dec 31, 2021 were selected from a database at the Nancy and James Grosfeld Cancer Genetics Center at Beaumont Health. Data on demographics, cancer type and molecular testing were retrospectively analyzed. Results: A total of 92 patients from 61 families were found to carry a pathogenic or likely pathogenic variant in PMS2. The mean age at testing was 54 (19 to 95). A majority (50) of the family were Caucasian, while the rest were African American (2), Middle Eastern (2), Multiracial (8). The most common variant was c.137G > T (p.Ser46Ile), seen in twelve of 61 families. Forty-two patients (45.6%) had a personal history of cancer, with a mean age at diagnosis of 63. Of these forty-two patients, four had multiple malignancies, including one patient with six separate cancers. The most common malignancies were breast (16), colon (12), followed by uterine cancer (8), pancreatic (4), prostate (3) and other cancers. The mean age of diagnosis of breast cancer was 56 (41 to 78), colon cancers was 57 (32 to 75), uterine cancer 59 (50 to 72). Tumor IHC was performed in thirteen cases and 11 demonstrated loss of PMS2 protein expression. MSI was performed in 8 cases and 5 were unstable and 3 were stable. Conclusions: This study reveals the the clinical spectrum of cancers in PMS2 related Lynch syndrome. The most common cancers were breast, colon and uterine cancer, with older age of diagnosis. There was evidence of a more severe phenotype, exemplified by a patient with six cancers, suggesting higher penetrance. Further research is needed to better characterize the clinical presentation of PMS2 related Lynch syndrome.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Hereditary Cancer

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Hereditary Cancer Syndromes

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10610)

DOI

10.1200/JCO.2022.40.16_suppl.10610

Abstract #

10610

Poster Bd #

484

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Metachronous colorectal cancers in Icelandic MSH6 and PMS2 Lynch syndrome carriers in 1955-2017: A population-based study.

First Author: Sigurdis Haraldsdottir

Abstract

2023 ASCO Annual Meeting

MSI analysis in patients with GIST with Lynch syndrome.

First Author: Silvia Gasperoni

Abstract

2019 ASCO Annual Meeting

Characterization of Lynch syndrome (LS) associated cancers in patients with immune dysfunction.

First Author: Shahla Bari

Abstract

2020 ASCO Virtual Scientific Program

Prevalence and clinical characterization of MMR-D/MSI extra-colonic cancers among germline PMS2 mutation carriers.

First Author: Alicia Latham